A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns Hopkins Kimmel Cancer Center have found.
Continue Reading
News Source: medicalxpress.com
Leave a Reply